Secura Bio Provides Corporate Update and Highlights Progress in its Phase 3 TERZO Study
Terzo remains on track for an interim data readout in early 2027, based on enrollment to date Achieved >30% annual growth in U.S. net sales of COPIKTRA(TM) through November BERKELEY HEIGHTS, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) — Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today provided a […]